Project Grant R21EB039295
- Federal Grant Award Summary New York University received a $1.34 million Project Grant from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), awarded August 21, 2025, with completion targeted for August 20, 2027. The grant supports research into fibronectin's role in oral cancer pain modulation, with the objective of identifying non-opioid therapeutic targets to address severe pain in oral cancer patients,...
- Federal Grant Award Summary Nano-Beads Protein Innovations, Inc. received a $620,174 Project Grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), awarded September 1, 2025, with completion expected by March 31, 2027. The project aims to develop NANO-AB, an innovative nanoscale biomaterial designed to advance monoclonal antibody (MAb) purification...
- Federal Grant Award Summary New York University School of Medicine received a $1.33 million Project Grant awarded August 12, 2025, from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The award funds the development of an artificial intelligence system designed to improve the diagnostic accuracy and cost-effectiveness of breast cancer screening by...
- Federal Grant Award Summary New York University received a $221,224 Project Grant award dated August 15, 2025, from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The project, titled "Developing and Testing Language Models with Cognitively Plausible Memory," will develop and validate artificial intelligence language models constrained by...
- Federal Project Grant Award Summary New York University received a $579,191 Project Grant from the National Science Foundation's Directorate for Engineering (CFDA 47.041) awarded February 15, 2026, with completion targeted for January 31, 2031. This CAREER (Faculty Early Career Development) award funds the development of innovative light-responsive biophotonic nanoprobes designed to study intracellular pain signaling pathways in sensory neurons. The project will establish molecular design...
- Federal Grant Award Summary New York University School of Medicine received a $114,562 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The award, effective June 1, 2026 through May 31, 2028, funds development of an advanced diffusion-weighted magnetic resonance imaging (DWI) framework designed to overcome critical limitations in...
- Federal Grant Award Summary The National Cancer Institute awarded New York University School of Medicine a $595,993 Project Grant (CFDA 93.395: Cancer Treatment Research) effective July 16, 2026, through July 31, 2031, to develop integrated biologic technologies for selective inhibition of intracellular oncoproteins. The project aims to establish a robust platform technology enabling direct and selective manipulation of intracellular driver oncoproteins and their interactions. The research...
- Federal Grant Award Summary The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded The Johns Hopkins University a $598,859 Project Grant effective June 1, 2026 through May 31, 2029 under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The award supports the development of Antigen-Presentation Modulating Nanoparticles (APM-NPs), a novel immune engineering platform technology designed to enhance T cell...
- Federal Grant Award Summary Lehigh University received a $616,375 Project Grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), awarded on April 14, 2026, with completion targeted for March 31, 2029. The award funds research to develop protease-responsive hydrogels that create cell-specific microenvironments within three-dimensional tissue...
- Federal Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded Rochester Institute of Technology $373,125 under the Biomedical Research and Research Training program (CFDA 93.859) to develop advanced computational and experimental systems for optimizing nanobody therapeutic design. The project, which commenced September 1, 2025 and extends through June 30, 2029, delivers a multi-objective engineering platform that simultaneously predicts and optimizes critical...
New York University received a $186,504 Project Grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), awarded July 3, 2026, with completion targeted for June 30, 2029. The project will develop the Biologics Sequential Nanoprecipitation (BIOSNAP) process, a continuous flow manufacturing system designed to efficiently encapsulate monoclonal antibodies and other biologics into polymeric nanoparticles for targeted drug delivery applications. This innovation addresses critical gaps in scalable nanoparticle manufacturing, which currently suffers from low therapeutic loading capacity and poor encapsulation efficiency, thereby enabling clinical translation of nanoparticle-based biologic delivery systems. The BIOSNAP technology specifically targets oral cancer pain management by delivering anti-protease-activated receptor 2 (PAR2) monoclonal antibodies directly to intracellular endosomal compartments within sensory neurons, offering a non-opioid therapeutic alternative to conventional pain management. Given oral cancer's significant burden—affecting over 59,000 Americans annually—and the escalating opioid crisis, this manufacturing advancement will support development of effective cancer pain therapies while establishing scalable production methods for future biologics delivery platforms.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $186.5k | 7/6/26 |